Signe Melsen Larsen

About

Signe Melsen Larsen is a leading urologic oncologist whose research focuses on reducing long-term treatment toxicity in testicular cancer. Her major contributions center on establishing primary retroperitoneal lymph node dissection (RPLND) as a safe, effective alternative to chemotherapy or radiotherapy for low-volume metastatic seminoma. Through her work with the Swedish Norwegian Testicular Cancer Group (SWENOTECA), Larsen has demonstrated that RPLND can achieve excellent oncological outcomes while sparing patients from the significant long-term morbidities associated with cytotoxic treatments. Her most cited paper (2024, 19 citations) reports on a population-based cohort showing the efficacy of this approach for stage IIA seminoma, while her collaborative study with the University of Cologne (2023, 7 citations) further validates RPLND for tumors up to 3 cm. Larsen’s research has been presented at major urology meetings, including the Journal of Urology, and is reshaping clinical guidelines by offering a surgery-first paradigm for select seminoma patients. Her work represents a pivotal shift toward personalized, toxicity-sparing management in testicular cancer, directly improving quality of life for young survivors.

Research Focus

Key Achievements

Top Papers

1. 1
   Primary Retroperitoneal Lymph Node Dissection as Treatment for Low-volume Metastatic Seminoma in a Population-based Cohort: The Swedish Norwegian Testicular Cancer Group Experience

   19 citations · 2024
2. 2
   Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA-IIC ≤3cm: Combined results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne.

   7 citations · 2023
3. 3
   MP33-04 THE EARLY RESULTS OF THE SWENOTECA (SWEDISH NORWEGIAN TESTICULAR CANCER GROUP) INTRODUCTION OF PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) IN SEMINOMA STAGE IIA-IIB ≤ 3cm

   3 citations · 2023

Key Collaborators

Contact & Links